Form 4: Director J. Erik Fyrwald Increases Stake in Eli Lilly

Eli Lilly director J. Erik Fyrwald acquired 10.78 shares of common stock through the company's directors' deferral plan.

Summary

• Director J. Erik Fyrwald acquired 10.78 shares of Eli Lilly common stock on April 20, 2026.
• The shares were acquired at a price of $919.90 per share.
• The acquisition was made in lieu of cash compensation under the Lilly Directors' Deferral Plan.
• The shares are held as stock units and will be settled in common stock following the director's separation from service.
• Following this transaction, the director's total beneficial ownership is 75,269.556 shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral, routine administrative filing regarding director compensation that does not signal a change in company strategy or financial health.

Positives

• Demonstrates alignment of interest between the director and shareholders through equity-based compensation.
• Reflects confidence in the company's long-term value by opting for stock units over cash compensation.

Negatives

• The transaction size is immaterial relative to the company's total market capitalization and the director's existing holdings.

Risks

• No specific risks were disclosed in this Form 4 filing.

Future Outlook

Not applicable as this is a routine insider transaction filing.

Industry Context

StockSavvy.ai notes that director equity deferral programs are standard corporate governance practices in the pharmaceutical industry, designed to ensure long-term alignment between board members and shareholders.

Comparison to Industry Standards

• The use of stock units in lieu of cash compensation is consistent with compensation practices at major pharmaceutical peers like Pfizer, Merck, and Bristol Myers Squibb.

Stakeholder Impact

• Minimal impact on shareholders as the transaction is a routine compensation adjustment.

Next Steps

• No future actions or milestones were mentioned in this filing.

Key Dates

Keywords

Eli Lilly, LLY, Insider Trading, Director Compensation, Equity Deferral